Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RZLT | PRESS-RELEASE | neutral | 5/10 | Rezolute reported Q3 fiscal 2026 net loss of $16.2M ($0.16 per share), narrower than the $18.9M loss a year ago, with ca | May 12, 2026 |
| PHVS | PRESS-RELEASE | neutral | 5/10 | Pharvaris reported Q1 2026 EPS of €-0.59 (IFRS), a narrower loss vs €-0.85 a year ago, with cash of €247M extended by a | May 12, 2026 |
| CAPR | PRESS-RELEASE | neutral | 5/10 | Capricor Therapeutics reported Q1 2026 EPS of -$0.59, missing consensus of -$0.54 by ~9.3%, with no revenue. The key cat | May 12, 2026 |
| BOLT | PRESS-RELEASE | bearish | 7/10 | Bolt Biotherapeutics reported Q1 2026 EPS of -$4.31, missing consensus of -$3.60 by 19.7%, and collaboration revenue col | May 12, 2026 |
| LBRX | PRESS-RELEASE | neutral | 4/10 | LB Pharmaceuticals reported Q1 2026 EPS of -$0.67, in line with consensus of -$0.67, and a net loss of $19.1M vs $5.3M a | May 12, 2026 |
| SLDB | PRESS-RELEASE | bearish | 6/10 | Solid Biosciences reported Q1 2026 EPS of -$0.53, a 20.9% miss versus the -$0.44 consensus, with net loss widening to $5 | May 12, 2026 |
| MAZE | PRESS-RELEASE | mixed | 5/10 | Maze Therapeutics reported Q1 2026 net loss of $24.2M ($0.45/share), missing consensus of $0.43/share by 4.7%, with lice | May 12, 2026 |
| VRCA | PRESS-RELEASE | bullish | 7/10 | Verrica Pharmaceuticals reported Q1 2026 revenue of $5.0M (beat consensus of $4.5M by 11.6%) and GAAP EPS of -$0.45 (bea | May 12, 2026 |
| NKTX | PRESS-RELEASE | neutral | 4/10 | Nkarta reported Q1 2026 EPS of -$0.37, a slight miss vs consensus of -$0.36, with no revenue. The company highlighted FD | May 12, 2026 |
| IKT | PRESS-RELEASE | mixed | 6/10 | Inhibikase reported a Q1 2026 net loss of $0.10 per share, slightly missing the $0.09 consensus, but operating expenses | May 12, 2026 |
| SKYE | PRESS-RELEASE | bearish | 7/10 | Skye Bioscience reported Q1 2026 EPS of -$0.32, missing consensus of -$0.29 by 10.3%, with a net loss of $12.5M vs $11.1 | May 12, 2026 |
| KURA | PRESS-RELEASE | bullish | 7/10 | Kura Oncology announced that updated Phase 1 KOMET-007 data for ziftomenib in frontline AML will be presented at EHA 202 | May 12, 2026 |
| EVAX | PRESS-RELEASE | neutral | 4/10 | Evaxion announced a poster presentation at the EHA 2026 Congress detailing preclinical data for EVX-04, an off-the-shelf | May 12, 2026 |
| BEAM | PRESS-RELEASE | bullish | 7/10 | Beam Therapeutics announced it will present updated biomarker data from the BEACON Phase 1/2 trial of ristoglogene autog | May 12, 2026 |
| CNTB | PRESS-RELEASE | bearish | 6/10 | Connect Biopharma reported Q1 2026 net loss of $0.34 per share, significantly wider than the consensus estimate of -$0.2 | May 12, 2026 |
| AKTX | PRESS-RELEASE | neutral | 4/10 | Akari Therapeutics announced the grant of a major European patent (No. 3684773B1) providing broad composition-of-matter | May 12, 2026 |
| PMVP | PRESS-RELEASE | bullish | 5/10 | PMV Pharma reported Q1 2026 EPS of -$0.34, beating consensus -$0.39 by 12.8%. The company also announced FDA Orphan Drug | May 12, 2026 |
| KLRS | PRESS-RELEASE | neutral | 4/10 | Kalaris Therapeutics reported Q1 2026 net loss per share of $(0.46), beating consensus of $(0.52) by 11.5%. The company | May 12, 2026 |
| ATAI | PRESS-RELEASE | mixed | 5/10 | AtaiBeckley reported Q1 2026 EPS of -$0.08, beating consensus of -$0.11 by 27%, and revenue of $954K, well above the $91 | May 12, 2026 |
| CRBP | PRESS-RELEASE | neutral | 4/10 | Corbus reported Q1 2026 net loss of $23.0M ($1.23/share), slightly missing consensus EPS of -$1.22. The company highligh | May 12, 2026 |
| RYTM | PRESS-RELEASE | neutral | 4/10 | Rhythm Pharmaceuticals presented positive clinical data for setmelanotide at ECE 2026, including significant BMI reducti | May 12, 2026 |
| INKT | PRESS-RELEASE | bullish | 7/10 | MiNK Therapeutics presented data at ASGCT 2026 showing its off-the-shelf iNKT cell therapy, agenT-797, produced context- | May 12, 2026 |
| COLL | PRESS-RELEASE | bullish | 7/10 | Collegium Pharmaceutical completed the acquisition of AZSTARYS, an ADHD treatment, from Corium Therapeutics for $650 mil | May 12, 2026 |
| HBIO | PRESS-RELEASE | neutral | 4/10 | Harvard Bioscience reported Q1 2026 revenue of $20.8M, down 4.6% YoY from $21.8M, and a GAAP net loss of $(3.4)M, improv | May 12, 2026 |
| SABS | PRESS-RELEASE | bearish | 7/10 | SAB Biotherapeutics reported Q1 2026 EPS of -$0.35, a 68.3% miss vs consensus of -$0.21, with net loss widening to $18.9 | May 12, 2026 |
| MREO | PRESS-RELEASE | bearish | 6/10 | Mereo BioPharma reported Q1 2026 EPS of -$0.01, missing the $0.00 consensus estimate, with revenue not explicitly stated | May 12, 2026 |
| XLO | PRESS-RELEASE | bullish | 7/10 | Xilio Therapeutics reported Q1 2026 results with collaboration revenue of $12.6M (up from $2.9M a year ago) and a net lo | May 12, 2026 |
| SGMT | PRESS-RELEASE | mixed | 6/10 | Sagimet Biosciences reported Q1 2026 EPS of -$0.33 (GAAP), beating consensus of -$0.35, with net loss narrowing to $10.7 | May 12, 2026 |
| BBIO | PRESS-RELEASE | bullish | 8/10 | BridgeBio announced NDA submission to the FDA for encaleret in ADH1, supported by positive Phase 3 CALIBRATE data showin | May 12, 2026 |
| UNCY | PRESS-RELEASE | bearish | 6/10 | Unicycive reported Q1 2026 EPS of -$0.54, significantly missing the consensus estimate of -$0.47, driven by a $4.8M non- | May 12, 2026 |